Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1923 1
1927 2
1928 4
1929 1
1930 1
1931 1
1932 1
1935 6
1936 1
1937 2
1939 2
1941 1
1942 2
1943 1
1944 1
1945 36
1946 121
1947 150
1948 186
1949 146
1950 187
1951 242
1952 341
1953 366
1954 468
1955 491
1956 452
1957 486
1958 495
1959 598
1960 582
1961 641
1962 634
1963 795
1964 1166
1965 949
1966 965
1967 1195
1968 1484
1969 1542
1970 1478
1971 1774
1972 1943
1973 1841
1974 1971
1975 2099
1976 2048
1977 2146
1978 2242
1979 2312
1980 2309
1981 2325
1982 2497
1983 2751
1984 3131
1985 3215
1986 3276
1987 3485
1988 3837
1989 4346
1990 4789
1991 4721
1992 4766
1993 4958
1994 5215
1995 5332
1996 5844
1997 5995
1998 6324
1999 6645
2000 7020
2001 7497
2002 7954
2003 9031
2004 9712
2005 11070
2006 11599
2007 12371
2008 12945
2009 13690
2010 15605
2011 17348
2012 19734
2013 20318
2014 22377
2015 24798
2016 25427
2017 25807
2018 27159
2019 28638
2020 31596
2021 31926
2022 29544
2023 27965
2024 9103

Text availability

Article attribute

Article type

Publication date

Search Results

524,912 results

Results by year

Filters applied: . Clear all
Page 1
Systemic and Radiation Therapy Approaches for Locally Advanced Non-Small-Cell Lung Cancer.
Higgins KA, Puri S, Gray JE. Higgins KA, et al. J Clin Oncol. 2022 Feb 20;40(6):576-585. doi: 10.1200/JCO.21.01707. Epub 2022 Jan 5. J Clin Oncol. 2022. PMID: 34985931 Review.
The treatment for locally advanced non-small-cell lung cancer has changed dramatically over the past several years, with consolidative immunotherapy after concurrent chemoradiation becoming the new standard of care. ...The current scientific lan …
The treatment for locally advanced non-small-cell lung cancer has changed dramatically over the past several yea …
Radiation and Systemic Therapy for Limited-Stage Small-Cell Lung Cancer.
Bogart JA, Waqar SN, Mix MD. Bogart JA, et al. J Clin Oncol. 2022 Feb 20;40(6):661-670. doi: 10.1200/JCO.21.01639. Epub 2022 Jan 5. J Clin Oncol. 2022. PMID: 34985935 Free PMC article. Review.
Progress in the overall treatment of small-cell lung cancer (SCLC) has moved at a slower pace than non-small-cell lung cancer. ...This is likely attributable in part to improvements in staging, including use of brain magnetic resonance imaging a …
Progress in the overall treatment of small-cell lung cancer (SCLC) has moved at a slower pace than non-small-cell …
Immunotherapy in unresectable stage III non-small-cell lung cancer: state of the art and novel therapeutic approaches.
Cortiula F, Reymen B, Peters S, Van Mol P, Wauters E, Vansteenkiste J, De Ruysscher D, Hendriks LEL. Cortiula F, et al. Ann Oncol. 2022 Sep;33(9):893-908. doi: 10.1016/j.annonc.2022.06.013. Epub 2022 Jun 28. Ann Oncol. 2022. PMID: 35777706 Free article. Review.
The standard of care for patients with stage III non-small-cell lung cancer (NSCLC) is concurrent chemoradiotherapy (CCRT) followed by 1 year of adjuvant durvalumab. ...In this review, we present the results of clinical trials …
The standard of care for patients with stage III non-small-cell lung cancer (NSCLC) is concurrent chem …
BRD4-IRF1 axis regulates chemoradiotherapy-induced PD-L1 expression and immune evasion in non-small cell lung cancer.
Wang J, Xu Y, Rao X, Zhang R, Tang J, Zhang D, Jie X, Zhu K, Wang X, Xu Y, Zhang S, Dong X, Zhang T, Yang K, Xu S, Meng R, Wu G. Wang J, et al. Clin Transl Med. 2022 Jan;12(1):e718. doi: 10.1002/ctm2.718. Clin Transl Med. 2022. PMID: 35083874 Free PMC article.
Reversing the chemoradiation-induced PD-L1 expression could provide a new strategy to achieve a greater anti-tumour effect of chemoradiotherapy. Here, we aimed to identify candidate small molecular inhibitors that might boost the anti-tumour immunity of chemoradiotherap …
Reversing the chemoradiation-induced PD-L1 expression could provide a new strategy to achieve a greater anti-tumour effect of chemoradiot …
Therapeutic hyperthermia.
Habash RWY. Habash RWY. Handb Clin Neurol. 2018;157:853-868. doi: 10.1016/B978-0-444-64074-1.00053-7. Handb Clin Neurol. 2018. PMID: 30459045 Review.
Its effect depends on the temperature and exposure time. The increasing number of applications and clinical trials at universities, clinics, and hospitals prove the feasibility and applicability of clinical therapeutic hyperthermia. ...The chapter conc …
Its effect depends on the temperature and exposure time. The increasing number of applications and clinical trials at universi …
Durvalumab Plus Concurrent Radiotherapy for Treatment of Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Phase 2 Nonrandomized Controlled Trial.
Tachihara M, Tsujino K, Ishihara T, Hayashi H, Sato Y, Kurata T, Sugawara S, Shiraishi Y, Teraoka S, Azuma K, Daga H, Yamaguchi M, Kodaira T, Satouchi M, Shimokawa M, Yamamoto N, Nakagawa K; West Japan Oncology Group (WJOG). Tachihara M, et al. JAMA Oncol. 2023 Nov 1;9(11):1505-1513. doi: 10.1001/jamaoncol.2023.3309. JAMA Oncol. 2023. PMID: 37676681 Clinical Trial.
IMPORTANCE: Administration of durvalumab after concurrent chemoradiotherapy is the standard treatment of unresectable, locally advanced non-small cell lung cancer (NSCLC); however, 20% to 30% of patients do not receive durvalumab because of adve …
IMPORTANCE: Administration of durvalumab after concurrent chemoradiotherapy is the standard treatment of unresectable, locally advanc …
Autophagy-related chemoradiotherapy sensitivity in non-small cell lung cancer (NSCLC).
Zadeh FA, Raji A, Ali SA, Abdelbasset WK, Alekhina N, Iswanto AH, Terefe EM, Jalil AT. Zadeh FA, et al. Pathol Res Pract. 2022 May;233:153823. doi: 10.1016/j.prp.2022.153823. Epub 2022 Feb 24. Pathol Res Pract. 2022. PMID: 35398616 Review.
NSCLC is the most common type of lung cancer. In recent years, advancements in chemoradiotherapy and immunotherapy have led to unprecedented survival benefits in some patients. ...Considering these inconsistencies, this study aimed to overview the intricacy of autop …
NSCLC is the most common type of lung cancer. In recent years, advancements in chemoradiotherapy and immunotherapy have led to …
Clinical features and risk factors for interstitial lung disease spreading in low-dose irradiated areas after definitive radiotherapy with or without durvalumab consolidation therapy for patients with non-small cell lung cancer.
Sakagami M, Inokuchi H, Mukumoto N, Itoyama H, Hamaura N, Yamagishi M, Mukumoto N, Matsuda S, Kabata D, Shibuya K. Sakagami M, et al. Radiat Oncol. 2023 May 22;18(1):87. doi: 10.1186/s13014-023-02276-7. Radiat Oncol. 2023. PMID: 37217919 Free PMC article.
BACKGROUND: The current standard of care for patients with unresectable locally advanced non-small cell lung cancer (NSCLC) is chemoradiotherapy (CRT) combined with durvalumab consolidation therapy. However, radiotherapy (RT) alway …
BACKGROUND: The current standard of care for patients with unresectable locally advanced non-small cell lung …
Chemoradiotherapy in Cancer Treatment: Rationale and Clinical Applications.
Rallis KS, Lai Yau TH, Sideris M. Rallis KS, et al. Anticancer Res. 2021 Jan;41(1):1-7. doi: 10.21873/anticanres.14746. Anticancer Res. 2021. PMID: 33419794 Review.
Chemoradiotherapy (CRT) refers to the combined administration of both chemotherapy and radiotherapy as an anticancer treatment. ...Considering the recent success achieved with anticancer immunotherapies including immune checkpoint inhibitors, the combination of CRT and imm …
Chemoradiotherapy (CRT) refers to the combined administration of both chemotherapy and radiotherapy as an anticancer treatment. ...Co …
Treatment of Locally Advanced Non-Small Cell Lung Cancer.
Tam K, Daly M, Kelly K. Tam K, et al. Hematol Oncol Clin North Am. 2017 Feb;31(1):45-57. doi: 10.1016/j.hoc.2016.08.009. Hematol Oncol Clin North Am. 2017. PMID: 27912833 Review.
Locally advanced non-small cell lung cancer is a heterogeneous disease with typically poor outcomes. ...Attempts to improve outcomes through induction, consolidation, or maintenance chemotherapy or radiation dose escalation have not demonstrated …
Locally advanced non-small cell lung cancer is a heterogeneous disease with typically poor outcomes. ...Attempts …
524,912 results
You have reached the last available page of results. Please see the User Guide for more information.